Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
VBR vs XBI: how they differ
VBR and XBI hold 2% of their weight in the same names, and XBI returned more over the year.
Vanguard Small-Cap Value Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VBR and XBI hold 2% of their money in the same securities at the same weight.
| Holding | VBR | XBI |
|---|---|---|
| Moderna Inc | 0.54% | 1.41% |
| United Therapeutics Corp | 0.25% | 0.93% |
| Praxis Precision Medicines Inc | 0.20% | 1.29% |
| Nuvalent Inc | 0.15% | 0.93% |
| Cogent Biosciences Inc | 0.14% | 1.15% |
| Apogee Therapeutics Inc | 0.08% | 1.49% |
| Spyre Therapeutics Inc | 0.07% | 1.10% |
| CG oncology Inc | 0.06% | 1.20% |
| Summit Therapeutics Inc | 0.04% | 1.01% |
| Dyne Therapeutics Inc | 0.03% | 0.86% |
| Iovance Biotherapeutics Inc | 0.02% | 0.56% |
| Only in VBR | Only in XBI |
|---|---|
| Jabil Inc 0.87% | Twist Bioscience Corp 1.41% |
| NRG Energy Inc 0.66% | Oruka Therapeutics Inc 1.38% |
| Tapestry Inc 0.64% | Kymera Therapeutics Inc 1.36% |
| Atmos Energy Corp 0.62% | Viking Therapeutics Inc 1.31% |
| Williams-Sonoma Inc 0.59% | Erasca Inc 1.27% |
| Smurfit Westrock PLC 0.52% | Revolution Medicines Inc 1.21% |
| F5 Inc 0.50% | Rhythm Pharmaceuticals Inc 1.20% |
| US Foods Holding Corp 0.48% | SELLAS Life Sciences Group Inc 1.19% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| VBR Vanguard Small-Cap Value Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | Small-Cap Value | SPDR S&P Biotech |
| Total return, 1 year | +16.3% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −1.2 pts | +46.5 pts |
| Expense ratio | 0.05% | 0.35% |
| Already in the S&P 500 | 30.5% | 8.5% |
| Holdings | 840 | 150 |
VBR in plain words
VBR is an index equity fund tracking the Small-Cap Value. Over the year to Sep 11, 2026 it returned +16.3% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.05% a year. By its holdings filed for Jun 30, 2026, 30% of the fund by weight is stocks the S&P 500 also holds, across 840 positions, with the top ten at 5.9%. It sat 3.8% below its high of Aug 14, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VBR or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, VBR returned +16.3% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VBR or XBI?
- VBR charges 0.05% a year and XBI charges 0.35%, so VBR is cheaper. Fees come from each fund's prospectus.
- How much do VBR and XBI overlap with the S&P 500?
- By their latest filed holdings, 30% of VBR and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VBR against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VBR-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources